MedTrace Logo

Individualized Infiximab Dosing-Proof of Concept Study

NCT02027727 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2017-07-19

No results posted yet for this study

Summary

The purpose of this study is to determine which early infliximab pharmacokinetic level is most associated with clinical remission at weeks 30 and 54 in pediatric IBD patients.

Conditions

  • Inflammatory Bowel Diseases

Interventions

OTHER

No Intervention

no intervention- tihs is an observational study

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Namita Singh, MD · Cedars-Sinai Medical Center

Eligibility

Min Age
6 Years
Max Age
23 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-05-31
Completion
2018-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02027727 on ClinicalTrials.gov